Title:
SALT, CRYSTALLINE FORM, SOLVATE AND HYDRATE OF COMPOUND
Document Type and Number:
WIPO Patent Application WO/2023/143486
Kind Code:
A9
Abstract:
The present invention relates to a salt, crystalline form, solvate or hydrate of 6-(ethylamino)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, also relates to a pharmaceutical composition containing the salt, crystalline form, solvate or hydrate, and also relates to a use of the salt, crystalline form, solvate or hydrate in the preparation of a drug for treating RET-related diseases.
Inventors:
WEN XIAOMING (CN)
CHENG HUIMIN (CN)
FANG LEI (CN)
CHENG HUIMIN (CN)
FANG LEI (CN)
Application Number:
PCT/CN2023/073504
Publication Date:
September 21, 2023
Filing Date:
January 28, 2023
Export Citation:
Assignee:
SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD (CN)
International Classes:
C07D519/00
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF:
Previous Patent: ELECTRONIC DEVICE AND CONTROL METHOD
Next Patent: EOC CURRENT SETTING CIRCUIT, CHIP AND ELECTRONIC DEVICE
Next Patent: EOC CURRENT SETTING CIRCUIT, CHIP AND ELECTRONIC DEVICE